Acimec SC Injection

Ivermectin is well absorbed when administered parenterally. Biological half-life is 2.9 days for cattle upon SQ administration. Therapeutic concentrations of ivermectin is maintained in body fluids for prolonged periods of time. Most of the administered dose of ivermectin is excreted in the feces, the remainder in the urine. Minimal residues are present in the muscle and kidneys, highest concentrations being detected in the liver and fat tissues. Residues in all tissues are extractable in nature with little or no macromolecularly bound drug or metabolites present. Ivermectin does not readily cross the blood-brain barrier of the mammal to affect the GABA within the central nervous system. In tests of brain concentration of the drug in cattle, radioactive residue assays revealed only minute traces of ivermectin. This was the lowest concentration of all tissues analyzed. There have been a number of cases of central nervous system depression in purebred and crossbred longhaired Collies. The reason for this breed susceptibility is not known. It has been postulated that the blood brain barrier in the Collie may be more permeable to ivermectin than in other species, allowing ivermectin to enter the central nervous system.

Ivermectin is a member of the macrocyclic lactone class of endectocides which have a unique mode of action. Compounds of the class bind selectively and with high affinity to glutamate-gated chloride ion channels which occur in invertebrate nerve and muscle cells. This leads to an increase in the permeability of the cell membrane to chloride ions with hyperpolarization of the nerve or muscle cell, resulting in paralysis and death of the parasite. Compounds of this class may also interact with other ligand-gated chloride channels, such as those gated by the neurotransmitter gamma-aminobutyric acid (GABA). The margin of safety for compounds of this class is attributable to the fact that mammals do not have glutamate-gated chloride channels, the macrocyclic lactones have a low affinity for other mammalian ligand-gated chloride channels and they do not readily cross the blood-brain barrier.

Ivermectin injection should be injected only by subcutaneous route (under the loose skin in front of or behind the shoulder).

• Ruminant: 1 ml per 50 kg body weight or 0.2 mg per kg body weight (Single injection). In case of humpsore the dose may be repeated after 28 days.
• Dog: 0.5 ml per 25 kg body weight or 0.2 mg per kg body weight. In the treatment of mange, the dosage should be as follows -
• Otodectic mange: Single injection.
• Sarcoptic mange: 2 injections at a 14 days interval.
• Demodectic mange and Fleas: 3 injections at a 7 days interval.
• Cat: 0.5 ml per 25 kg body weight or 0.2 mg per kg body weight (Single injection).
• Horse: 1ml per 50 kg body weight or 0.2 mg per kg body weight (Single injection). Or as advised by the registered veterinarian.

Patients with a history of hypersensitivity to Ivermectin or to other macrocyclic lactones are contra-indicated for this drug.

Transitory discomfort has been observed in some cattle following subcutaneous administration. A low incidence of soft tissue swelling at the injection site has been observed. These reactions have disappeared without treatment.

Ivermectin Injection is considered to be safe to use during pregnancy. Reproductive studies performed in dogs, horses, cattle and swine have not demonstrated adverse effects to fetuses. Reproductive performance in male animals is also apparently unaltered.

Acimec is not for intravenous or intramuscular use. Use sterile equipment and sanitize the injection site by applying a suitable disinfectant. Clean, properly disinfected needles should be used to reduce the potential for injection site infections. Do not treat cattle within 35 days of slaughter. Because a withdrawal time in milk has not been established, do not use in female dairy cattle of breeding age.

Store between 15°C-30°C temperature and dry place. Protect from light & keep out of reach of children.